Telehealth vs In-Person Buprenorphine Referral After ED Presentation: Landmark RCT Targets the Critical Gap in OUD Continuity of Care

References

1. 1.University of California, Davis. (2025). In person vs telehealth opioid use disorder treatment after patients leave the emergency department (NCT06961058). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06961058
2. 2.D'Onofrio, G., O'Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015). Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: A randomized clinical trial. JAMA, 313(16), 1636–1644. https://doi.org/10.1001/jama.2015.3474
3. 3.Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2014(2), CD002207. https://doi.org/10.1002/14651858.CD002207.pub4
4. 4.Centers for Disease Control and Prevention. (2023). Drug overdose deaths in the United States, 2002–2022 (NCHS Data Brief No. 491). National Center for Health Statistics. https://www.cdc.gov/nchs/products/databriefs/db491.htm
5. 5.Huskamp, H. A., Busch, A. B., Souza, J., Uscher-Pines, L., Rose, S., Wilcock, A., Landon, B. E., & Mehrotra, A. (2018). How is telemedicine being used in opioid and other substance use disorder treatment? Health Affairs, 37(12), 1940–1947. https://doi.org/10.1377/hlthaff.2018.05134
6. 6.Tofighi, B., Sindhu, S. S., Chemi, C., Dickson, V. V., & Lee, J. D. (2019). Perspectives on the shifting patient-provider relationships and use of digital health technology amongst primary care patients receiving buprenorphine treatment. Substance Abuse Treatment, Prevention, and Policy, 14(1), 45. https://doi.org/10.1186/s13011-019-0240-9